<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>åˆ¶è¯æ—¥æŠ¥ - 2026-01-22</title>
    <style>
        :root, [data-theme="minimal"] {
            --bg-primary: #ffffff;
            --bg-secondary: #f5f5f7;
            --text-primary: #1d1d1f;
            --text-secondary: #86868b;
            --accent: #0071e3;
            --accent-hover: #0077ed;
            --border: #d2d2d7;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.05);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        [data-theme="pharma-blue"] {
            --bg-primary: #f0f4f8;
            --bg-secondary: #ffffff;
            --text-primary: #2d3748;
            --text-secondary: #718096;
            --accent: #2b6cb0;
            --accent-hover: #2c5282;
            --border: #e2e8f0;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.1), 0 2px 4px -1px rgba(0, 0, 0, 0.06);
            --header-bg: linear-gradient(135deg, #1a365d 0%, #2b6cb0 100%);
            --header-text: #ffffff;
        }

        [data-theme="warm"] {
            --bg-primary: #faf8f5;
            --bg-secondary: #ffffff;
            --text-primary: #451a03;
            --text-secondary: #78716c;
            --accent: #d97706;
            --accent-hover: #b45309;
            --border: #e7e5e4;
            --card-shadow: 0 1px 3px 0 rgba(0, 0, 0, 0.1);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "SF Pro Display", "SF Pro Text", "Helvetica Neue", "PingFang SC", "Microsoft YaHei", sans-serif;
            background: var(--bg-primary);
            color: var(--text-primary);
            line-height: 1.5;
            -webkit-font-smoothing: antialiased;
        }

        .container {
            max-width: 980px;
            margin: 0 auto;
            padding: 0 22px;
        }

        /* Header */
        header {
            padding: 80px 0 60px;
            text-align: center;
        }

        .logo {
            font-size: 48px;
            margin-bottom: 16px;
        }

        h1 {
            font-size: 48px;
            font-weight: 600;
            letter-spacing: -0.02em;
            margin-bottom: 8px;
        }

        .subtitle {
            font-size: 21px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        /* Stats */
        .stats-bar {
            display: flex;
            justify-content: center;
            gap: 48px;
            padding: 32px 0;
            margin: 40px 0;
            border-top: 1px solid var(--border);
            border-bottom: 1px solid var(--border);
        }

        .stat {
            text-align: center;
        }

        .stat-value {
            font-size: 32px;
            font-weight: 600;
            color: var(--text-primary);
        }

        .stat-label {
            font-size: 14px;
            color: var(--text-secondary);
            margin-top: 4px;
        }

        /* Analysis Section */
        .analysis {
            background: var(--bg-secondary);
            border-radius: 18px;
            padding: 32px;
            margin-bottom: 48px;
        }

        .analysis h2 {
            font-size: 24px;
            margin-bottom: 16px;
        }

        .analysis-content {
            font-size: 17px;
            line-height: 1.7;
            color: var(--text-secondary);
        }

        /* Category Section */
        .category {
            margin-bottom: 56px;
        }

        .category-header {
            display: flex;
            align-items: baseline;
            gap: 12px;
            margin-bottom: 24px;
            padding-bottom: 12px;
            border-bottom: 1px solid var(--border);
        }

        .category-title {
            font-size: 28px;
            font-weight: 600;
        }

        .category-title-en {
            font-size: 17px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        .category-count {
            background: var(--bg-secondary);
            color: var(--text-secondary);
            padding: 4px 12px;
            border-radius: 20px;
            font-size: 14px;
            margin-left: auto;
        }

        /* News Card */
        .news-card {
            background: var(--bg-primary);
            border: 1px solid var(--border);
            border-radius: 18px;
            padding: 28px;
            margin-bottom: 16px;
            transition: all 0.3s ease;
        }

        .news-card:hover {
            box-shadow: var(--card-shadow);
            transform: translateY(-2px);
        }

        .news-card h3 {
            font-size: 21px;
            font-weight: 600;
            margin-bottom: 12px;
            line-height: 1.4;
        }

        .news-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 16px;
            margin-bottom: 16px;
            font-size: 14px;
            color: var(--text-secondary);
        }

        .news-source {
            color: var(--accent);
            font-weight: 500;
        }

        .news-importance {
            letter-spacing: 2px;
        }

        .news-summary {
            font-size: 17px;
            color: var(--text-secondary);
            line-height: 1.6;
            margin-bottom: 16px;
        }

        .news-link {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            color: var(--accent);
            text-decoration: none;
            font-size: 17px;
            font-weight: 500;
            transition: color 0.2s;
        }

        .news-link:hover {
            color: var(--accent-hover);
        }

        .news-link::after {
            content: "â†’";
            transition: transform 0.2s;
        }

        .news-link:hover::after {
            transform: translateX(4px);
        }

        /* Footer */
        footer {
            text-align: center;
            padding: 48px 0;
            color: var(--text-secondary);
            font-size: 14px;
            border-top: 1px solid var(--border);
            margin-top: 48px;
        }

        footer p {
            margin-bottom: 8px;
        }

        /* Language Flag */
        .lang-flag {
            font-size: 16px;
            margin-right: 8px;
        }

        /* Date Filter */
        .date-filter {
            display: flex;
            justify-content: center;
            gap: 8px;
            flex-wrap: wrap;
            margin-bottom: 32px;
        }

        .date-btn {
            padding: 8px 16px;
            border: 1px solid var(--border);
            border-radius: 20px;
            background: var(--bg-primary);
            color: var(--text-secondary);
            font-size: 14px;
            cursor: pointer;
            transition: all 0.2s ease;
            display: flex;
            flex-direction: column;
            align-items: center;
            min-width: 70px;
        }

        .date-btn:hover {
            border-color: var(--accent);
            color: var(--accent);
        }

        .date-btn.active {
            background: var(--accent);
            border-color: var(--accent);
            color: white;
        }

        .date-btn.weekend {
            background: var(--bg-secondary);
        }

        .date-btn.weekend.active {
            background: var(--accent);
        }

        .date-btn .weekday {
            font-size: 12px;
            opacity: 0.8;
        }

        .date-btn .date-display {
            font-weight: 500;
        }

        .filter-count {
            text-align: center;
            color: var(--text-secondary);
            font-size: 14px;
            margin-bottom: 24px;
        }

        .news-card.hidden {
            display: none;
        }

        /* Theme Switcher */
        .theme-switcher {
            position: fixed;
            top: 20px;
            right: 20px;
            display: flex;
            gap: 8px;
            background: var(--bg-secondary);
            padding: 8px;
            border-radius: 12px;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.1);
            z-index: 1000;
        }

        .theme-btn {
            width: 32px;
            height: 32px;
            border: 2px solid transparent;
            border-radius: 8px;
            cursor: pointer;
            transition: all 0.2s ease;
            position: relative;
        }

        .theme-btn:hover {
            transform: scale(1.1);
        }

        .theme-btn.active {
            border-color: var(--accent);
        }

        .theme-btn[data-theme="minimal"] {
            background: linear-gradient(135deg, #ffffff 50%, #0071e3 50%);
        }

        .theme-btn[data-theme="pharma-blue"] {
            background: linear-gradient(135deg, #1a365d 50%, #2b6cb0 50%);
        }

        .theme-btn[data-theme="warm"] {
            background: linear-gradient(135deg, #faf8f5 50%, #d97706 50%);
        }

        /* Responsive */
        @media (max-width: 734px) {
            header {
                padding: 48px 0 40px;
            }

            h1 {
                font-size: 32px;
            }

            .subtitle {
                font-size: 17px;
            }

            .stats-bar {
                gap: 24px;
            }

            .stat-value {
                font-size: 24px;
            }

            .category-title {
                font-size: 24px;
            }

            .news-card {
                padding: 20px;
            }

            .news-card h3 {
                font-size: 19px;
            }
        }
    </style>
</head>
<body>
    <!-- Theme Switcher -->
    <div class="theme-switcher">
        <button class="theme-btn active" data-theme="minimal" title="ç®€çº¦ç™½"></button>
        <button class="theme-btn" data-theme="pharma-blue" title="åŒ»è¯è“"></button>
        <button class="theme-btn" data-theme="warm" title="æš–è‰²è°ƒ"></button>
    </div>

    <div class="container">
        <header>
            <div class="logo">ğŸ’Š</div>
            <h1>åˆ¶è¯æ—¥æŠ¥</h1>
            <p class="subtitle">Pharma Daily Â· 2026-01-22 <span style="font-size: 14px; opacity: 0.7;">(US Eastern / EST)</span></p>
        </header>

        <div class="stats-bar">
            <div class="stat">
                <div class="stat-value">102</div>
                <div class="stat-label">æ–°é—»æ€»æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">4</div>
                <div class="stat-label">ç±»åˆ«æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">2026-01-23 03:41</div>
                <div class="stat-label">æ›´æ–°æ—¶é—´</div>
            </div>
        </div>

        <!-- Date Filter -->
        <div class="date-filter">
            <button class="date-btn active" data-filter="all">
                <span class="weekday">å…¨éƒ¨</span>
                <span class="date-display">All</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-16">
                <span class="weekday">å‘¨äº”</span>
                <span class="date-display">01/16</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-01-17">
                <span class="weekday">å‘¨å…­</span>
                <span class="date-display">01/17</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-01-18">
                <span class="weekday">å‘¨æ—¥</span>
                <span class="date-display">01/18</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-19">
                <span class="weekday">å‘¨ä¸€</span>
                <span class="date-display">01/19</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-20">
                <span class="weekday">å‘¨äºŒ</span>
                <span class="date-display">01/20</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-21">
                <span class="weekday">å‘¨ä¸‰</span>
                <span class="date-display">01/21</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-22">
                <span class="weekday">å‘¨å››</span>
                <span class="date-display">01/22</span>
            </button>
            
        </div>
        <div class="filter-count" id="filterCount"></div>

        
        <section class="analysis">
            <h2>ğŸ“Š ä»Šæ—¥æ¦‚è§ˆ</h2>
            <div class="analysis-content">
                <h3>ğŸ“Š AI æ™ºèƒ½åˆ†æ</h3>
<h4>ä»Šæ—¥æ¦‚è§ˆ</h4>
<p>ä»Šæ—¥åˆ¶è¯è¡Œä¸šå‘ˆç°å¤šå…ƒåŒ–åŠ¨æ€ï¼Œç›‘ç®¡æ”¿ç­–ä¸é‡å¤§å•†ä¸šäº¤æ˜“æˆä¸ºç„¦ç‚¹ã€‚FDAå‘å¸ƒå¤šå‘æ€§éª¨é«“ç˜¤è¯ç‰©å¼€å‘æ–°æŒ‡å—ï¼Œæœ‰æœ›åŠ é€Ÿç›¸å…³ç–—æ³•å®¡æ‰¹ï¼›GSKä»¥22äº¿ç¾å…ƒæ”¶è´­RAPT Therapeuticsï¼Œå¼ºåŒ–è¿‡æ•é¢†åŸŸå¸ƒå±€ï¼›åŒæ—¶ï¼Œç”Ÿç‰©ç±»ä¼¼è¯å¸‚åœºå‰æ™¯ä¹è§‚ï¼Œè€ŒValnevaå› å®‰å…¨æ€§é—®é¢˜æ’¤å›åŸºå­”è‚¯é›…çƒ­ç–«è‹—ã€‚</p>
<h4>ğŸ”¥ é‡ç‚¹æ–°é—»</h4>
<p><strong>4. J&J praises new FDA guidance to speed development of multiple myeloma drugs</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: æ”¿ç­–æ³•è§„<br>
   - FDAå‘å¸ƒæ–°æŒ‡å—ï¼Œå…è®¸ä½¿ç”¨å¾®å°æ®‹ç•™ç—…ä½œä¸ºä¸»è¦ç»ˆç‚¹ï¼Œå¯èƒ½åŠ é€Ÿå¤šå‘æ€§éª¨é«“ç˜¤è¯ç‰©å®¡æ‰¹ï¼Œå¯¹è¡Œä¸šç ”å‘è·¯å¾„æœ‰é‡å¤§å½±å“ã€‚</p>
<p><strong>17. GSK to buy Rapt in $2.2B deal for food allergy drug</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€<br>
   - GSKä»¥22äº¿ç¾å…ƒæ”¶è´­RAPT Therapeuticsï¼Œè·å¾—å®éªŒæ€§é£Ÿç‰©è¿‡æ•è¯ç‰©ï¼Œæ˜¯CEOä¸Šä»»åé¦–ç¬”é‡å¤§äº¤æ˜“ï¼Œæˆ˜ç•¥æ„ä¹‰æ˜¾è‘—ã€‚</p>
<p><strong>8. Biosimilar execs optimistic about future for US biosims as Sandoz locks in on â€˜golden decadeâ€™ to come</strong> â­â­â­â­<br>
   - ç±»åˆ«: å¸‚åœºåˆ†æ<br>
   - FDAæ–°æŒ‡å—ç®€åŒ–ç”Ÿç‰©ç±»ä¼¼è¯å¼€å‘ï¼Œè¡Œä¸šé«˜ç®¡å¯¹å¸‚åœºå‰æ™¯ä¹è§‚ï¼Œé¢„ç¤ºç”Ÿç‰©ç±»ä¼¼è¯å¯èƒ½è¿›å…¥å¿«é€Ÿå¢é•¿æœŸã€‚</p>
<p><strong>12. Valneva withdraws chikungunya vaccine Ixchiq from US amid new FDA investigation</strong> â­â­â­â­<br>
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹<br>
   - Valnevaå› FDAè°ƒæŸ¥æ–°çš„ä¸¥é‡ä¸è‰¯ååº”è€Œè‡ªæ„¿æ’¤å›åŸºå­”è‚¯é›…çƒ­ç–«è‹—ï¼Œå‡¸æ˜¾ç–«è‹—å®‰å…¨æ€§ç›‘ç®¡çš„é‡è¦æ€§ã€‚</p>
<p><strong>1. Samsung Bio sticks landing on 2025 as it becomes first Korean biopharma to hit 2T won profit threshold</strong> â­â­â­â­<br>
   - ç±»åˆ«: å¸‚åœºåˆ†æ<br>
   - ä¸‰æ˜Ÿç”Ÿç‰©åˆ¶å‰‚æˆä¸ºé¦–å®¶å¹´åˆ©æ¶¦çªç ´2ä¸‡äº¿éŸ©å…ƒçš„éŸ©å›½ç”Ÿç‰©åˆ¶è¯å…¬å¸ï¼Œæ˜¾ç¤ºCDMOè¡Œä¸šå¼ºåŠ²å¢é•¿å’Œé¾™å¤´åœ°ä½ã€‚</p>
<h4>ğŸ“ åˆ†ç±»æ‘˜è¦</h4>
<p><strong>æ–°è¯ç ”å‘</strong> (Drug R&D): IntraBioçš„Aqneursaåœ¨ç½•è§ç—…é¢†åŸŸå–å¾—IIIæœŸæˆåŠŸï¼Œå¹¶è·æ¬§ç›Ÿæ‰¹å‡†ï¼›Corvusçš„æ¹¿ç–¹å£æœè¯æ—©æœŸæ•°æ®ç§¯æï¼›Definiumæ¨è¿›LSDè¯ç‰©æ²»ç–—ç²¾ç¥å¥åº·é€‚åº”ç—‡ï¼›Corxelè·å¾—2.87äº¿ç¾å…ƒèèµ„å¼€å‘å£æœGLP-1å‡è‚¥è¯ã€‚<br>
<strong>ä¸´åºŠè¯•éªŒ</strong> (Clinical Trials): IntraBioå®£å¸ƒå…¶æ²»ç–—å…±æµå¤±è°ƒ-æ¯›ç»†è¡€ç®¡æ‰©å¼ ç—‡çš„è¯ç‰©åœ¨å…³é”®IIIæœŸè¯•éªŒä¸­æ”¹å–„è¿åŠ¨åŠŸèƒ½ï¼Œå°†å¯»æ±‚FDAæ‰¹å‡†ï¼›CEPIèµ„åŠ©3000ä¸‡ç¾å…ƒä¸é»˜å…‹ç­‰åˆä½œæ”¹è¿›åŸƒåšæ‹‰ç–«è‹—ã€‚</p>
<h4>ğŸ”® æ˜æ—¥å…³æ³¨</h4>
<p>å…³æ³¨FDAå¯¹Valnevaç–«è‹—å®‰å…¨è°ƒæŸ¥çš„è¿›å±•ã€GSKæ”¶è´­RAPTçš„åç»­æ•´åˆã€ä»¥åŠFDAæ–°æŒ‡å—å¯¹å¤šå‘æ€§éª¨é«“ç˜¤è¯ç‰©ç ”å‘çš„å®é™…å½±å“ã€‚åŒæ—¶ï¼Œç•™æ„å›½ä¼šå¯èƒ½é€šè¿‡çš„PBMæ”¹é©æ³•æ¡ˆå’Œæ”¿åºœèµ„åŠ©æ³•æ¡ˆä¸­çš„åŒ»è¯ç›¸å…³æ”¿ç­–ã€‚</p>
            </div>
        </section>
        

        <main>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç»¼åˆ</h2>
                    <span class="category-title-en"></span>
                    <span class="category-count">40 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Samsung Bio sticks landing on 2025 as it becomes first Korean biopharma to hit 2T won profit threshold
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-22 07:36</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">CDMO Samsung Biologics grew sales more than 30% last year to around 4.6 trillion Korean won ($3.1 billion) and lifted its 2025 operating profit to roughly 2.07 trillion won ($1.4 billion). Samsung Bio is now the first Korean biotech or pharmaceutical company to surpass the 2 trillion won annual profit threshold, local news outlets reported this week.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/samsung-bio-sticks-landing-2025-it-becomes-first-korean-biopharma-hit-2-trillion-won-profit" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Pfizer sells its stake in GSK&#39;s ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 09:29</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Five weeks after telling investors to expect a revenue decline in 2026, Pfizer has found a quick funding fix, selling off its stake in GSKâ€™s ViiV Healthcare. The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms of the agreement, Shionogi will pick up Pfizerâ€™s shares for $2.125 billion, with GSK gaining a special dividend of $250 million.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/pfizer-sells-its-stake-gsks-viiv-19b-shionogi-upping-its-ante-hiv-focused-company" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        CEPI bankrolls $30M Ebola vaccine collaboration with Merck, SK Bioscience and others
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-22 10:54</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The project, which involves Merck, SK Bioscience, Hilleman Laboratories and CDMO IDT Biologika, aims to make Merck&#39;s current Ebola vaccine easier to manufacture and store, prompting broader global accessibility.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/cepi-bankrolls-30m-ebola-vaccine-collaboration-merck-sk-biosciences-and-others" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        IntraBio&#39;s Aqneursa, on a roll with EU approval, races toward another rare disease indication with phase 3 win
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-21 11:04</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The company announced a phase 3 win in the rare neurodegenerative disease Ataxia-telangiectasia on the same day it snagged a key European approval in the drug&#39;s original indication of Niemann-Pick disease type C.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/intrabios-aqneursa-roll-eu-approval-races-toward-another-rare-disease-indication-phase-3-win" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Biosimilar execs optimistic about future for US biosims as Sandoz locks in on â€˜golden decadeâ€™ to come
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-21 17:07</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Executives from top U.S. biosimilar makers are optimistic about the future of U.S. biosimilar adoption as recent FDA guidance seeks to streamline biosimilar development and potentially dissipate the upcoming â€œbiosimilar void.â€</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/biosimilar-execs-remain-optimistic-state-us-biosimilars-while-sandoz-locks-golden-decade" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Led by Darzalex surge, J&amp;amp;J expects revenue to reach $100B in 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-21 11:20</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Led by cancer standout Darzalex, Johnson &amp;amp; Johnson projects that its 2026 revenue will reach between $100 billion and $101 billion. With J&amp;amp;J also forecasting double-digit revenue increases by the end of the decade, the drugmaker may be on its way to kicking off a $100-billion-plus annual revenue streak.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/led-darzalex-surge-jj-expects-revenue-reach-100b-2026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Definium defines mental health applications for LSD in new awareness campaign
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 11:30</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">As it inches closer to FDA submissions for its psychedelic drug candidate, Definium Therapeutics is laying the groundwork for a future launch with an educational push about the pharmaceutical potential of LSD.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/definium-defines-mental-health-applications-lsd-new-awareness-campaign" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Roche scales Genentech&#39;s North Carolina site to $2B in major obesity market play
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 11:47</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Roche is more than doubling its total commitment to a future facility for its Genentech unit to approximately $2 billion. The plant, being built in Holly Springs, North Carolina, will be used to crank out next-generation drugs for metabolic conditions like obesity, Roche has said.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/roche-beefs-investment-genentechs-future-nc-obesity-drug-factory-2b" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Valneva withdraws chikungunya vaccine Ixchiq from US amid new FDA investigation
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 09:53</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Following an FDA marketing suspension, Valneva has decided to voluntarily withdraw its chikungunya vaccine Ixchiq in the U.S. The FDA has also opened an investigation into a newly reported serious adverse event.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/valneva-withdraws-chikungunya-vaccine-ixchiq-us-amid-new-fda-investigation" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: The number of new drug shortages in U.S. hits lowest level in 20 years, but myriad problems remain
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 17:40</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower than the all-time high reached in the beginning of 2024.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/22/medicines-pharma-biotech-shortages-hospitals-injectables/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about Canada speeding drug reviews, Novo Nordisk ads, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-21 14:14</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Health Canada is planning to speed up reviews of some drugs by piggybacking on the decisions of foreign regulators, including possibly the U.S. FDA</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/21/canada-vaccines-novo-eczema-diabetes/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: GSK to buy RAPT Therapeutics, maker of food allergy treatment, in $2.2B deal
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-20 08:01</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">GSK is buying RAPT Therapeutics in a deal worth $2.2 billion, picking up an experimental medicine for food allergies.</p>
                    
                    <a href="https://www.statnews.com/2026/01/20/gsk-rapt-therapeutics-acquisition-food-allergy-prophylaxis-ozureprubart/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: FDA delays reviews for two drugs in new voucher program
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-16 14:36</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">And more biotech news, brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/16/biotech-news-fda-delays-review-in-voucher-program/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about FDA voucher worries, weight loss drugs and jet fuel, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-16 14:30</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Some major drugmakers are hesitating to participate in the Trump administration&#39;s speedier review program for new medicines over possible legal risks</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/16/trump-fda-voucher-obesity-novo-lilly-covid/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Global pharma manufacturing output surged in &#39;25 in &#39;front-loading&#39; response to US tariff threats: report
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-22 15:19</span>
                        
                    </div>
                    
                    <p class="news-summary">While the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026, according to a new report from financial services firm Atradius.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/pharma-manufacturing-output-surged-25-countries-braced-us-tariffs-atradius" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Invivyd teams up with Olympic skier Lindsey Vonn for antibody education
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-22 10:54</span>
                        
                    </div>
                    
                    <p class="news-summary">As Lindsey Vonnâ€™s comeback run heads toward a peak with Team USA at the upcoming 2026 Winter Olympics, Invivyd is adding the professional skier to its team, too.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/invivyd-teams-olympic-skier-lindsey-vonn-antibody-education" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lundbeck â€˜not willing to compromiseâ€™ on M&amp;amp;A strategy after missed Avadel attempt: exec
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-22 10:23</span>
                        
                    </div>
                    
                    <p class="news-summary">Despite falling short in its recent bid to snatch Avadel from Alkermes, Lundbeck is signaling to investors that itâ€™s not desperate for deals and will not lower its standards for future M&amp;amp;A transactions.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/lundbeck-not-willing-compromise-ma-strategy-after-missed-avadel-attempt" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Trump&#39;s Davos drug pricing claims decried as &#39;fake news&#39; by French presidency
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-22 09:57</span>
                        
                    </div>
                    
                    <p class="news-summary">After U.S. President Donald Trump took the stage at the World Economic Forum this week to tout the supposed success of his tariff-tinged trade negotiations, the French presidency has pushed back against a drug pricing claim that itâ€™s branding â€œfake news.â€</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/trumps-davos-drug-pricing-claims-decried-fake-news-french-presidency" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        In J&amp;amp;J talc litigation, N.J. court-appointed official recommends allowing expert testimony
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-21 15:13</span>
                        
                    </div>
                    
                    <p class="news-summary">In Johnson &amp;amp; Johnson&#39;s long-running talc litigation, a court-appointed special master has recommended that plaintiffs should be able to present testimony from expert witnesses who can speak to scientific evidence backing their claims. The decision could negatively impact the company&#39;s defense of lawsuits from those who claim Johnsonâ€™s Baby Powder caused their cancer.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/jj-talc-litigation-nj-court-recommends-allow-expert-testimony" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        UPDATE: In quick reversal, Trump calls off tariff threat related to Greenland pursuit
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 09:55</span>
                        
                    </div>
                    
                    <p class="news-summary">Only a few days after threatening to impose new tariffs on a group of European countries related to his pursuit of Greenland, the president has called off the threat.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/trumps-new-tariff-threats-around-greenland-threaten-upend-eu-trade-deal" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Pfizer CEO lays blame for US vaccine woes on RFK Jr.&#39;s &#39;anti-science&#39; stance: WSJ
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-21 09:46</span>
                        
                    </div>
                    
                    <p class="news-summary">While much of the biopharma industry has spent the past 12 months treading lightly around the Trump administration and the tumult it has wrought on U.S. medical research and regulation, Pfizerâ€™s CEO cut to the chase this week in a blatant rebuke of HHS Secretary Robert F. Kennedy Jr., according to The Wall Street Journal.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/pfizer-ceo-lays-blame-us-vaccine-woes-anti-science-rfk-jr-wsj" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Rising Stars: Regeneronâ€™s Catie Matthews on updating marketing strategy to meet the AI boom
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 12:30</span>
                        
                    </div>
                    
                    <p class="news-summary">In a Q&amp;amp;A for Fierce Pharma Marketingâ€™s â€œRising Starsâ€ series, Catie Matthews suggested that marketers should embrace artificial intelligence in their own lives.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/rising-stars-regenerons-catie-matthews-updating-marketing-strategy-amid-ai-boom" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        GSK licenses Alteogen enzyme in bid to develop subQ Jemperli
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 14:08</span>
                        
                    </div>
                    
                    <p class="news-summary">GSK, through its oncology subsidiary Tesaro, is handing over $20 million upfront to Alteogen for global rights to the Korean biotechâ€™s novel hyaluronidase ALT-B4. Tesaro plans to use ALT-B4 to develop and potentially market a subcutaneous form of the ascendant cancer med Jemperli.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/gsk-offers-alteogen-285m-subq-jemperli-licensing-pact" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Takeda&#39;s neuroscience field force hit with layoffs as key patent loss looms for Trintellix
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 13:14</span>
                        
                    </div>
                    
                    <p class="news-summary">Takeda is executing another round of layoffs, cutting 243 roles in the U.S. The company is preparing for an upcoming patent loss on depression drug Trintellix.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/takeda-cuts-243-us-workers-generic-competition-looms-trintellix" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Supreme Court agrees to review &#39;skinny label&#39; battle between Hikma, Amarin over generic Vascepa
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 11:27</span>
                        
                    </div>
                    
                    <p class="news-summary">The U.S. Supreme Court will hear a case involving the &#34;skinny label&#34; practice of generic drug makers, with its review particularly relating to Hikma&#39;s marketing of its generic version of Amarin&#39;s Vascepa.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/supreme-court-agrees-review-skinny-label-battle-hikma-amarin-over-generic-vascepa" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Curia&#39;s Mass. plant closure to eliminate 81 jobs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 17:08</span>
                        
                    </div>
                    
                    <p class="news-summary">Curia Global is laying off 81 employees as part of its plan to shut down its drug product development and manufacturing facility in Burlington, Massachusetts, according to a Worker Adjustment and Retraining Notification.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/curia-plant-shutdown-massachusetts-forces-lay-81" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Apiject signs lease for new generics blow-fill-seal manufacturing facility in N.C.
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 08:33</span>
                        
                    </div>
                    
                    <p class="news-summary">Prefilled drug delivery device specialist Apiject has signed a lease for a new site in Apex, North Carolina, that will house two blow-fill-seal production lines.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/apiject-signs-lease-new-generics-blow-fill-seal-facility-north-carolina" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo riffs on Appleâ€™s â€˜Get a Macâ€™ ads in Ozempic push starring Justin Long, John Hodgman
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-16 15:28</span>
                        
                    </div>
                    
                    <p class="news-summary">Amid a viral social media trend glorifying the halcyon days of 2016, Novo Nordisk has gone back an extra decade to find inspiration for its latest direct-to-consumer Ozempic campaign.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/novo-riffs-apples-get-mac-ads-ozempic-push-starring-justin-long-john-hodgman" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Health insurance execs shift blame for costly, confusing health care system
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 20:11</span>
                        
                    </div>
                    
                    <p class="news-summary">Health insurance execs blame the high cost of health care on hospitals, doctors, and prescription drugs.</p>
                    
                    <a href="https://www.statnews.com/2026/01/22/health-insurance-execs-blame-high-costs-hospitals-doctors-pharma/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: France rebuffs Trump over drug-pricing boast
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 15:58</span>
                        
                    </div>
                    
                    <p class="news-summary">And more biotech news from The Readout newsletter</p>
                    
                    <a href="https://www.statnews.com/2026/01/22/biotech-news-2/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about Europeâ€™s pharma supply chain, stopping GLP-1 drugs, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 14:26</span>
                        
                    </div>
                    
                    <p class="news-summary">Many patients using GLP-1 drugs like Wegovy may not regain lost weight quickly when they stop treatment, an analysis of real-world data shows</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/22/europe-insulin-novo-weight-cvs-pharmacies/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Anthony Letai says NCI is more stable than perceived and is heading for a big year
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Anthony Letai says the National Cancer Institute is more stable than perceived and is heading for a big year.</p>
                    
                    <a href="https://www.statnews.com/2026/01/22/national-cancer-institute-director-anthony-letai-q-and-a/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Novo strikes deal for diabetes cell therapies
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-21 14:53</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news, brought to you by The Readout newsletter</p>
                    
                    <a href="https://www.statnews.com/2026/01/21/biotech-news-novo-nordisk-acquires-aspect-biosystems/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Congress revives health care deal with PBM reforms
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-20 15:31</span>
                        
                    </div>
                    
                    <p class="news-summary">This is the web edition of D.C. Diagnosis, STAT&#39;s twice-weekly newsletter about the politics and policy of health and medicine.</p>
                    
                    <a href="https://www.statnews.com/2026/01/20/congress-revives-health-care-deal-pbm-reforms-dc-diagnosis-newsletter/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Benefit from Modernaâ€™s skin cancer immunotherapy endures
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-20 14:47</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news brought to you by the Readout Newsletter</p>
                    
                    <a href="https://www.statnews.com/2026/01/20/biotech-news-moderna-merck-skin-cancer-mrna/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about drug prices in Europe, a cancer vaccine, and much more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-20 14:20</span>
                        
                    </div>
                    
                    <p class="news-summary">U.S. pharmaceutical companies are stepping up their campaign for higher drug prices in Europe, in some cases threatening to withhold new medicines</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/20/pharma-prices-china-gsk-aids-cancer-vaccine-europe/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Florida proposes cutting eligibility for an AIDS drug program, causing panic
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-20 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">In a surprise move, Florida officials have proposed drastically reducing eligibility for the state AIDS drug assistance program.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/20/florida-hiv-aids-gilead-health-insurance/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Congress revives bipartisan health care proposal, including drug middlemen provisions
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-20 01:03</span>
                        
                    </div>
                    
                    <p class="news-summary">Elements of a health care deal that was blown up by Elon Musk are getting a fresh look in Congress.</p>
                    
                    <a href="https://www.statnews.com/2026/01/19/bipartisan-health-care-package-pharmacy-benefit-manager/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Supreme Court agrees to review â€˜skinny labelingâ€™ and generic drug access
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-16 21:03</span>
                        
                    </div>
                    
                    <p class="news-summary">The Supreme Court agreed to review a controversy over so-called skinny labels for medicines, a decision that will be closely watched for its implications for the availability of generic medicines.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/16/scotus-generics-patents-supreme-court-amarin-hikma/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-16">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Up and down the ladder: The latest comings and goings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-16 17:00</span>
                        
                    </div>
                    
                    <p class="news-summary">From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/16/pharma-biotech-jobs-novo-bristol-astrazeneca/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">æ–°è¯ç ”å‘</h2>
                    <span class="category-title-en">Drug R&amp;D</span>
                    <span class="category-count">34 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Another biopharma tried buying Amicus before BioMarin&#39;s $4.8B deal
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 15:16</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The road to Amicus Therapeuticsâ€™ $4.8 billion exit to BioMarin last month included a previously undisclosed acquisition offer from another biopharma, quiet dinners between CEOs and a months-long push to settle a ...</p>
                    
                    <a href="https://endpoints.news/another-biopharma-tried-buying-amicus-before-biomarins-4-8b-deal/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        J&amp;J praises new FDA guidance to speed development of multiple myeloma drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 18:35</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Johnson &amp;amp; Johnson, which has several drugs approved for multiple myeloma, praised the FDA&#39;s just-released draft guidance on how the agency will allow the use of minimal residual disease as a primary endpoint for accelerated ...</p>
                    
                    <a href="https://endpoints.news/jj-praises-new-fda-guidance-to-speed-development-of-multiple-myeloma-drugs/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        IntraBio says rare disease drug passes Phase 3, will seek FDA approval
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 16:05</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">IntraBio said Wednesday that its treatment improved motor function for a rare genetic disorder called ataxia-telangiectasia as part of a pivotal study. The Austin, TX-based biotech told Endpoints News it plans to submit an application ...</p>
                    
                    <a href="https://endpoints.news/intrabio-says-rare-disease-drug-passes-phase-3-will-seek-fda-approval/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Investors load Corxel with $287M for a â€˜differentiatedâ€™ obesity pill
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-22 19:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be as effective in spurring weight loss as injectable therapies.</p>
                    
                    <a href="https://www.biopharmadive.com/news/corxel-oral-glp1-vincentage-series-d-china-deal/810242/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA lays out new path to speed development of multiple myeloma drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-22 16:36</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change that could accelerate cell therapies and other new medicines.&amp;nbsp;</p>
                    
                    <a href="https://www.biopharmadive.com/news/fda-multiple-myeloma-accelerated-approval-pathway/810219/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Corvus shares nearly triple on positive data for eczema pill
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-21 16:39</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed with the injectable biologic Dupixent.</p>
                    
                    <a href="https://www.biopharmadive.com/news/corvus-soquelitinib-phase-1-data-eczema-pill/810080/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Valneva to withdraw Chikungunya vaccine from US amid safety woes
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-20 16:47</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The decision comes months after the FDA had suspended the vaccine&amp;rsquo;s license. One analyst speculated the company might shelve the product altogether.&amp;nbsp;</p>
                    
                    <a href="https://www.biopharmadive.com/news/valneva-fda-withdrawl-application-chikungunya-Ixchiq-vaccine/809994/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        GSK to buy Rapt in $2.2B deal for food allergy drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-20 15:57</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines businesses.</p>
                    
                    <a href="https://www.biopharmadive.com/news/gsk-rapt-acquire-food-allergy-prophylaxis-drug-ozureprubart/809956/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Kaileraâ€™s Ron Renaud on how a China-linked startup can compete in obesity
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-20 12:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">In an interview with BioPharma Dive, the veteran biotech CEO said there remains a &amp;ldquo;significant opportunity&amp;rdquo; for young companies in a market dominated by Novo Nordisk and Eli Lilly.</p>
                    
                    <a href="https://www.biopharmadive.com/news/kailera-ron-renaud-obesity-hengrui-rebupatide/809798/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Roche boosts NC factory investment to $2B; Rentschler CEO steps down
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 15:39</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Rocheâ€™s Genentech is topping up its investment into its Holly Springs, NC, factory to reach nearly $2 billion. The extra investment will also add an additional 100 jobs at the site ...</p>
                    
                    <a href="https://endpoints.news/roche-boosts-nc-factory-investment-to-2b-rentschler-ceo-steps-down/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Government funding bill features PBM reforms, voucher reauthorization
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-20 19:14</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The House is set to vote this week on a bipartisan bill to keep the government open beyond Jan. 30, with new proposals to change how pharmacy benefit managers operate and to reauthorize a lapsed ...</p>
                    
                    <a href="https://endpoints.news/government-funding-bill-features-pbm-reforms-voucher-reauthorization/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Bristol Myers buys into Januxâ€™s â€˜maskedâ€™ T cell engagers
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-22 17:00</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Worth up to $850 million, the partnership provides &amp;ldquo;further validation&amp;rdquo; for Janux at a time of heightened investor scrutiny regarding the potential of its top drug, one analyst wrote.&amp;nbsp;</p>
                    
                    <a href="https://www.biopharmadive.com/news/janux-bristol-myers-partnership-t-cell-engagers-cancer/810227/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Fosun-funded Hygtia Therapeutics licenses Insilicoâ€™s NLRP3 inhibitor for Parkinsonâ€™s
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 12:14</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A biotech funded by Shanghai Fosun Pharmaceutical is licensing a preclinical asset developed by Insilico Medicine in the NLRP3 space, which has garnered industry interest in recent months. Hygtia Therapeutics will get half the global ...</p>
                    
                    <a href="https://endpoints.news/fosun-funded-hygtia-therapeutics-licenses-insilicos-nlrp3-inhibitor-for-parkinsons/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        BioMarin vets form Mendra to â€˜modernizeâ€™ rare disease drug development
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-22 16:02</span>
                        
                    </div>
                    
                    <p class="news-summary">Backed with $82 million and led by two of BioMarin&amp;rsquo;s former executives, Mendra&amp;nbsp;plans to acquire rare disease assets and use AI to help accelerate their development.</p>
                    
                    <a href="https://www.biopharmadive.com/news/mendra-rare-disease-biotech-startup-ai-biomarin-financing/810204/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        J&amp;J eyes $100B in sales amid gains for cancer, immune drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-21 16:04</span>
                        
                    </div>
                    
                    <p class="news-summary">Amid patent expirations, litigation and tariff costs, J&amp;amp;J says it expects more growth ahead, fueled in part by its blood cancer medicines and a closely watched psoriasis pill.</p>
                    
                    <a href="https://www.biopharmadive.com/news/johnson-johnson-2025-earnings-sales-cancer-immune-drugs/810097/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Moderna cancer vaccine holds up; IO Biotech considers a sale
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-21 15:38</span>
                        
                    </div>
                    
                    <p class="news-summary">Long-term data suggest Moderna&amp;rsquo;s personalized melanoma shot provides &amp;ldquo;durable tumor control,&amp;rdquo; one analyst said. Elsewhere, Insilico Medicine partnered with a startup on a popular drug target.</p>
                    
                    <a href="https://www.biopharmadive.com/news/moderna-melanoma-io-biotech-nlrp3-think-pfizer-novavax/809958/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        High court picked Hikmaâ€™s â€˜skinny labelâ€™ fight after letting the issue â€˜percolateâ€™
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 19:53</span>
                        
                    </div>
                    
                    <p class="news-summary">Generic and brand-name drugmakers have been divided for decades over the use of â€œskinny labelsâ€ to bring lower-cost drugs to market. Now, the Supreme Court is taking up the issue. Itâ€™s wading into a case ...</p>
                    
                    <a href="https://endpoints.news/high-court-picked-hikmas-skinny-label-fight-after-letting-the-issue-percolate/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drugmakers spent less on Washington lobbying in 2025&#39;s final quarter
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 18:35</span>
                        
                    </div>
                    
                    <p class="news-summary">The top five biopharma company spenders on congressional lobbying spent slightly less in Washington in the final quarter of 2025 than they did in the previous quarter, the latest Senate disclosures show. Pfizer and Johnson ...</p>
                    
                    <a href="https://endpoints.news/drugmakers-spent-less-on-washington-lobbying-in-2025s-final-quarter/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Corcept&#39;s drug extends patients&#39; lives in key ovarian cancer study
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 16:08</span>
                        
                    </div>
                    
                    <p class="news-summary">Corcept Therapeutics said its experimental drug cut the risk of death by 35% for patients with a challenging form of ovarian cancer when added on top of chemotherapy, notching an important win after the California ...</p>
                    
                    <a href="https://endpoints.news/corcepts-drug-extends-patients-lives-in-key-ovarian-cancer-study/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        China-founded pharma Corxel raises up to $287M for oral GLP-1
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 16:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Since its 2019 founding, Corxel Pharmaceuticals has evolved from focusing on the China market to eyeing the world. The biopharma, founded in Shanghai but now headquartered in New Jersey, has raised as much as ...</p>
                    
                    <a href="https://endpoints.news/china-founded-pharma-corxel-raises-up-to-287m-for-oral-glp-1/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Health insurance CEOs head to DC
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 15:39</span>
                        
                    </div>
                    
                    <p class="news-summary">We donâ€™t know if President Donald Trump made good on plans to meet with major health insurers yet, but their CEOs are slated to testify today before two congressional committees ...</p>
                    
                    <a href="https://endpoints.news/health-insurance-ceos-head-to-dc/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Bristol Myers signs deal with Janux on T cell engager for $50M upfront
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 15:15</span>
                        
                    </div>
                    
                    <p class="news-summary">Janux Therapeutics has found a new partner. The San Diego-based biotech is teaming up with Bristol Myers Squibb on a solid tumor program, but the target is not yet disclosed. Bristol ...</p>
                    
                    <a href="https://endpoints.news/bristol-myers-signs-deal-with-janux-on-t-cell-engager-for-50m-upfront/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Erasca, Corvus, BioAge target $500M+ offerings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 14:43</span>
                        
                    </div>
                    
                    <p class="news-summary">Plus, news about Ipsen, Galderma, PAQ Therapeutics and Resolve M Therapeutics: ğŸ’° Public offering roundup: Erasca is selling more than 22 million shares at $10 apiece, targeting $225 million in ...</p>
                    
                    <a href="https://endpoints.news/erasca-corvus-bioage-target-500m-offerings/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        #JPM26: Hua Medicine plots diabetes drug expansion in China and beyond
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 12:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Shanghai-based Hua Medicine wants to capture a greater share of the global diabetes market with a different approach from popular GLP-1 medicines. Many newer diabetes drugs mimic gut hormones to regulate glucose. Hua&#39;s drug for ...</p>
                    
                    <a href="https://endpoints.news/hua-medicine-plots-diabetes-drug-expansion-in-china-and-beyond/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        BioMarin vets spearhead new biotech with $82M for rare disease drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 12:00</span>
                        
                    </div>
                    
                    <p class="news-summary">A fresh biotech has raised $82 million to scour the landscape of rare disease medicines that need a new home for further development and apply lessons from executives&#39; experiences at BioMarin. The Bay Area startup ...</p>
                    
                    <a href="https://endpoints.news/biomarin-vets-spearhead-new-biotech-with-82m-for-rare-disease-drugs/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        The status of EU drug price talks depends on who you ask
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 20:33</span>
                        
                    </div>
                    
                    <p class="news-summary">One of the main questions for drugmakers entering 2026, and one they hope tilts in their favor, is whether the US will successfully pressure Europe to raise the price it pays for drugs. Three weeks ...</p>
                    
                    <a href="https://endpoints.news/the-status-of-eu-drug-price-talks-depends-on-who-you-ask/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Johnson &amp; Johnson brushes off MFN impact, sees strong growth for 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 16:43</span>
                        
                    </div>
                    
                    <p class="news-summary">As the calendar turns from JPM to quarterly reports, earnings bellwether Johnson &amp;amp; Johnson makes its return for 2026. The focus this time? How biopharma will react to a slate of most favored nation deals ...</p>
                    
                    <a href="https://endpoints.news/johnson-johnson-brushes-off-mfn-impact-sees-strong-growth-for-2026/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Tanabe pill delays blood disorder; enGene adds up to $100M from loans
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 16:25</span>
                        
                    </div>
                    
                    <p class="news-summary">Plus, news about IO, ErVimmune, Affibody, Clasp Therapeutics and Infinitopes: ğŸ’Š Tanabe Pharmaâ€™s pill succeeds in rare blood conditions: The biotechâ€™s oral melanocortin-1 receptor delayed the onset of symptoms in a ...</p>
                    
                    <a href="https://endpoints.news/tanabe-pill-delays-blood-disorder-engene-adds-up-to-100m-from-loans/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        #JPM26: Regeneron, Lilly, Summit on rivals crowding into same targets
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 14:00</span>
                        
                    </div>
                    
                    <p class="news-summary">There are countless diseases lacking a single good treatment, but drugmakers are still herding into the same targets, particularly in chasing after megablockbusters. George Yancopoulos, the outspoken co-founder and chief scientific officer of Regeneron, is ...</p>
                    
                    <a href="https://endpoints.news/jpm26-regeneron-lilly-summit-on-rivals-crowding-into-same-targets/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Exclusive: Claim Health raises $4.4M to help home care providers get paid
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 14:00</span>
                        
                    </div>
                    
                    <p class="news-summary">After an initial wave of AI startups that automated specific administrative tasks in healthcare, companies are now racing to handle the entire process. Claim Health, which aims to manage every step of how home care ...</p>
                    
                    <a href="https://endpoints.news/exclusive-claim-health-raises-4-4m-to-help-home-care-providers-get-paid/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Think Bioscience gets $55M to unearth new drug pockets
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 12:00</span>
                        
                    </div>
                    
                    <p class="news-summary">A Boulder, CO-based startup is searching for previously undiscovered footholds â€” not on rocks, but on molecules. Think Bioscience has raised a $55 million Series A led by investors including Regeneron Ventures ...</p>
                    
                    <a href="https://endpoints.news/think-bioscience-gets-55m-to-unearth-new-drug-pockets/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        EU Parliament adopts stricter drug stockpiling rules under Critical Medicines Act
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-20 18:55</span>
                        
                    </div>
                    
                    <p class="news-summary">The European Parliament has adopted proposals aimed at reducing critical drug shortages across the EU, including stricter stockpiling rules and incentives for companies to boost manufacturing capacity. On Tuesday, the European Parliament adopted the Critical ...</p>
                    
                    <a href="https://endpoints.news/eu-parliament-adopts-stricter-drug-stockpiling-rules-under-critical-medicines-act/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Valneva withdraws chikungunya vaccine from US
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-20 18:37</span>
                        
                    </div>
                    
                    <p class="news-summary">Valneva has taken its chikungunya vaccine out of the US market, withdrawing its suspended product and a now-halted post-marketing study. The company said Monday that it decided to voluntarily withdraw its ...</p>
                    
                    <a href="https://endpoints.news/valneva-withdraws-chikungunya-vaccine-from-us/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Clinician groups ask court to overturn CDC&#39;s childhood vaccine overhaul
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-20 15:54</span>
                        
                    </div>
                    
                    <p class="news-summary">Leading clinician groups are asking a federal court to undo the US overhaul of the childhood vaccine schedule, calling the move the â€œmost egregious, reckless, and dangerousâ€ action that HHS Secretary Robert F. Kennedy Jr ...</p>
                    
                    <a href="https://endpoints.news/clinician-groups-ask-court-to-overturn-cdcs-childhood-vaccine-overhaul/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç›‘ç®¡å®¡æ‰¹</h2>
                    <span class="category-title-en">Regulatory</span>
                    <span class="category-count">20 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Questions and Answers: Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 17:27</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Questions and Answers: Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations</p>
                    
                    <a href="http://www.fda.gov/drugs/pharmaceutical-quality-resources/questions-and-answers-integration-fda-facility-evaluation-and-inspection-program-human-drugs-concept" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Registered Outsourcing Facilities
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 14:32</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Discover FDA&#39;s comprehensive list of registered outsourcing facilities engaged in human drug compounding. Get the latest updates, compliance guidelines, and resources to ensure safe, high-quality compounded medications. Explore regulations and stay informed with verified facility details.</p>
                    
                    <a href="http://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Bodynplant - Online Advisory Letter
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 14:21</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA Online advisory letter issued to Bodynplant/bodynplant.com for serious disease claims, including: cancer, diabetes, and HIV-AIDS</p>
                    
                    <a href="http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/bodynplant-online-advisory-letter" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        What&#39;s New Related to Drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 22:55</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Want to know what&#39;s new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.</p>
                    
                    <a href="http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug Trials Snapshots
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 22:45</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Drug Trials Snapshots: breaking down the what, how and why. Drug Trials Snapshots is part of an overall FDA effort to make demographic data more available and transparent.</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Importing Liquid Cough and Cold Medicine from India
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 17:56</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA is aware of news reports of devastating, ongoing diethylene glycol (DEG) and ethylene glycol (EG) contamination in childrenâ€™s cough and cold medicine in India.</p>
                    
                    <a href="http://www.fda.gov/drugs/human-drug-imports/importing-liquid-cough-and-cold-medicine-india" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug Alerts and Statements
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 15:01</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA Drug Alerts and Statements</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-safety-and-availability/drug-alerts-and-statements" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA Announces PreCheck Implementation Roadmap
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 15:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The U.S. Food and Drug Administration announced that it will begin accepting applications on Feb. 1, 2026 for the PreCheck Pilot Program, a program to strengthen the domestic pharmaceutical supply chain. Learn more.</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-precheck-implementation-roadmap" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        C3TI Compass (Knowledge Repository)
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 14:46</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Centralized knowledge repository for clinical trial innovation</p>
                    
                    <a href="http://www.fda.gov/about-fda/cder-center-clinical-trial-innovation-c3ti/c3ti-compass-knowledge-repository" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Bayesian Statistical Analysis (BSA) Demonstration Project
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 14:45</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">C3TI aims to increase experience in Bayesian statistical methods in simple trial settings across sponsors, CDER clinical reviewers, and CDER statisticians, including deepening an understanding of their applicability, opportunities, and challenges.</p>
                    
                    <a href="http://www.fda.gov/about-fda/cder-center-clinical-trial-innovation-c3ti/bayesian-statistical-analysis-bsa-demonstration-project" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Clinical Outcome Assessment (COA): Frequently Asked Questions
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 13:16</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Clinical Outcome Assessments (COA) Frequently Asked Questions</p>
                    
                    <a href="http://www.fda.gov/about-fda/clinical-outcome-assessment-coa-frequently-asked-questions" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        List of Drug Master Files (DMFs)
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 20:02</span>
                        
                    </div>
                    
                    <p class="news-summary">The list is updated quarterly.&amp;nbsp;Changes are made to the DMF activity status, DMF type, holder name, and subject.</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-master-files-dmfs/list-drug-master-files-dmfs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug User Fee Amendments
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 17:38</span>
                        
                    </div>
                    
                    <p class="news-summary">This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.</p>
                    
                    <a href="http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug Facilities, Sites and Organization Lists
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 17:35</span>
                        
                    </div>
                    
                    <p class="news-summary">Generic Drug Facilities, Sites and Organization Lists</p>
                    
                    <a href="http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Products Claiming to &#34;Cure&#34; Cancer Are a Cruel Deception
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 14:03</span>
                        
                    </div>
                    
                    <p class="news-summary">Many ads on social media and &#34;healthy&#34; websites claim their products can cure cancer. They cannot.</p>
                    
                    <a href="http://www.fda.gov/consumers/consumer-updates/products-claiming-cure-cancer-are-cruel-deception" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Advisory Letters
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 13:44</span>
                        
                    </div>
                    
                    <p class="news-summary">Advisory Letters</p>
                    
                    <a href="http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/advisory-letters" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novel Drug Approvals for 2025
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 22:45</span>
                        
                    </div>
                    
                    <p class="news-summary">Innovative drugs often mean new treatment options for patients and advances in health care for the American public.</p>
                    
                    <a href="http://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug Trials Snapshots KYGEVVI
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 22:43</span>
                        
                    </div>
                    
                    <p class="news-summary">Drug Trials Snapshots KYGEVVI</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-kygevvi" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Compounding Quality Center of Excellence | Instructor-Led Trainings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 21:32</span>
                        
                    </div>
                    
                    <p class="news-summary">The Compounding Quality Center of Excellenceâ€™s free in-person training programs target outsourcing facility staff and offer continuing education credits. The training will open for state regulators and pharmacy compounders if space is available.</p>
                    
                    <a href="http://www.fda.gov/drugs/compounding-quality-center-excellence/compounding-quality-center-excellence-instructor-led-trainings" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Quality and Regulatory Predictability: Shaping USP Standards - 12/11/2025
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 16:26</span>
                        
                    </div>
                    
                    <p class="news-summary">This discussion will show how USP public standards strengthen quality, streamline development, support regulatory compliance, and overall, increase regulatory predictability for drugs.</p>
                    
                    <a href="http://www.fda.gov/drugs/news-events-human-drugs/quality-and-regulatory-predictability-shaping-usp-standards-12112025" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">å•†ä¸šåŠ¨æ€</h2>
                    <span class="category-title-en">Business/M&amp;A</span>
                    <span class="category-count">8 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ErVimmune raises 17m euros in funding to develop cancer vaccine
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-22 14:10</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The vaccine could be created as a ready-to-use product, rather than needing to be personalised</p>
                    
                    <a href="https://pharmatimes.com/news/ervimmune-raises-17m-euros-in-funding-to-develop-cancer-vaccine/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-19">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-19 14:34</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Decision introduces zolbetuximab for eligible patients in NHS Scotland</p>
                    
                    <a href="https://pharmatimes.com/news/scottish-medicines-consortium-becomes-first-in-uk-to-adopt-new-precision-gastric-cancer-treatment/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AAX Biotech and Vascurie announce new neuro-oncology collaboration
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-20 12:41</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The collaboration will help to advance a pipeline of antibody candidates</p>
                    
                    <a href="https://pharmatimes.com/news/aax-biotech-and-vascurie-announce-new-neuro-oncology-collaboration/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-19">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-19 14:42</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Company prepares marketing submission after treatment shows strong efficacy</p>
                    
                    <a href="https://pharmatimes.com/news/nxera-pharma-reports-positive-results-from-phase-3-insomnia-trial-in-south-korea/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-22 12:36</span>
                        
                    </div>
                    
                    <p class="news-summary">The PM Awards celebrate creativity in pharmaceutical marketing and healthcare communications</p>
                    
                    <a href="https://pharmatimes.com/news/book-your-tickets-and-join-the-pm-society-for-the-40th-pm-awards-on-20-march-2026/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sun Pharmaâ€™s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-21 12:13</span>
                        
                    </div>
                    
                    <p class="news-summary">More than 71% of patients treated with Unloxcyt achieved disease control</p>
                    
                    <a href="https://pharmatimes.com/news/sun-pharmas-unloxcyt-now-available-in-us-for-advanced-cutaneous-squamous-cell-carcinoma/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Peter Llewellyn-Davies
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-21 12:02</span>
                        
                    </div>
                    
                    <p class="news-summary">ARTCLINE appoints Peter Llewellyn-Davies as Chairman of its Supervisory Board</p>
                    
                    <a href="https://pharmatimes.com/appointments/peter-llewellyn-davies/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Venner Shipley announces opening of new Bristol office
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-20 12:42</span>
                        
                    </div>
                    
                    <p class="news-summary">The firm already has a number of offices across the UK and Europe</p>
                    
                    <a href="https://pharmatimes.com/news/venner-shipley-announces-opening-of-new-bristol-office/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
        </main>

        <footer>
            <p>Generated by <strong>Pharma Daily</strong> - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ</p>
            <p>2026-01-23 03:41</p>
        </footer>
    </div>

    <script>
    (function() {
        // ========== Theme Switcher ==========
        const themeBtns = document.querySelectorAll('.theme-btn');
        const savedTheme = localStorage.getItem('pharma-daily-theme') || 'minimal';

        function setTheme(theme) {
            document.body.setAttribute('data-theme', theme);
            themeBtns.forEach(btn => {
                btn.classList.toggle('active', btn.getAttribute('data-theme') === theme);
            });
            localStorage.setItem('pharma-daily-theme', theme);
        }

        // Apply saved theme on load
        setTheme(savedTheme);

        themeBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                setTheme(this.getAttribute('data-theme'));
            });
        });

        // ========== Date Filter ==========
        const filterBtns = document.querySelectorAll('.date-btn');
        const newsCards = document.querySelectorAll('.news-card');
        const filterCount = document.getElementById('filterCount');
        const categories = document.querySelectorAll('.category');

        function updateFilter(selectedDate) {
            let visibleCount = 0;

            newsCards.forEach(card => {
                const cardDate = card.getAttribute('data-date');
                if (selectedDate === 'all' || cardDate === selectedDate) {
                    card.classList.remove('hidden');
                    visibleCount++;
                } else {
                    card.classList.add('hidden');
                }
            });

            // Hide empty categories
            categories.forEach(category => {
                const visibleCards = category.querySelectorAll('.news-card:not(.hidden)');
                category.style.display = visibleCards.length > 0 ? 'block' : 'none';

                // Update category count
                const countSpan = category.querySelector('.category-count');
                if (countSpan) {
                    countSpan.textContent = visibleCards.length + ' æ¡';
                }
            });

            // Update filter count display
            if (selectedDate === 'all') {
                filterCount.textContent = '';
            } else {
                filterCount.textContent = `æ˜¾ç¤º ${visibleCount} æ¡æ–°é—»`;
            }
        }

        filterBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                filterBtns.forEach(b => b.classList.remove('active'));
                this.classList.add('active');
                updateFilter(this.getAttribute('data-filter'));
            });
        });
    })();
    </script>
</body>
</html>